The Tali Digital Ltd (ASX: TD1) share price jumped 45% higher to 5.4 cents yesterday after the company announced it inked an investment and advertising agreement with Brand Capital International (BCI) and The Times Group of India.
Today, the Tali Digital share price continues its upward surge following the company's announcement of its first Japanese patent by the Japan Patent Office (JPO). At the time of writing, Tali Digital shares have increased another 3.7% to 5.6 cents.
What is Tali Digital?
Tali Digital is a micro cap medical technology company, focused on the development of game-based training programs to assess and treat childhood attention difficulties. Its programs have been proven through scientifically validated clinical trials to improve attention capabilities by strengthening underlying attentional processes.
The company has achieved a number of significant milestones including the commercial roll out of its 'Tali Detect' and 'Tali Train' products, regulatory clearance in the United States and European Union, and app store release in India.
The Tali share price has almost doubled in the last two weeks from 3 cents to its current level of 5.6 cents. This follows the company's positive market updates and a significant increase in trading volumes for its shares.
What's moving the Tali share price again today?
Tali shares are on the move again after the company reported the Japanese patent covers its Tali Detect and Tali Train products as well as its soon to be released Tali maintenance program.
Japan is the world's third-largest market for ADHD treatments and is growing at more than 20% annually. ADHD is a major issue among the Japanese population of 15 million children under 15 years.
According to Tali, this is the first time a patent has been granted in Japan for a cognitive assessment and training system, capable of improving attentional skills for sustained periods.
Tali sees favourable Japanese market dynamics where non-pharmaceutical based approaches are the preference in ADHD treatment. A CCHR report, 'ADHD labelling and treatment of Children in Japan' highlights that treatment with medication for ADHD is less favourable than psychological treatment. The report goes on to recommend "that psychotropic drugs are prescribed as a measure of last resort and only after an individualised assessment of the best interests of the child".
Tali sees the granting of the Japanese patent as a significant opportunity and potential market advantage for its digital therapeutics. Tali Digital Managing Director Glenn Smith said:
The granting of the patent secures Tali's intellectual property position and paves the way for the Company to enter the Japanese market via a partnership model. With over 15 million children in Japan, under the age of 15 years, the country represents a large potential market for the range of Tali cognitive assessment tools. The ability to leverage our patents strengthens our software in multiple regions and highlights the global opportunity of our product suite.
